Sarcoma (Leiomyosarcoma and Endometrial Stromal Sarcoma) of the Corpus Uteri; Uterus, NOS (excluding Placenta and Adenosarcoma, Carcinoma, and Carcinosaroma)
| Primary Site | Histology | Staging Type | 
|---|---|---|
| C540-C543, C548-C549, C559 | 8800, 8890-8898, 8900-8921, 8930-8931, 8935 | TNM 7 and Summary Stage | 
| C540-C543, C548-C549, C559 | 8801-8889, 8899, 8922-8929, 8932, 8934, 8936-8941, 8959-8974, 8982-9136, 9141-9582 | Summary Stage only | 
If you are working with a site/histology that only summary stages and you need to directly code it, please use the SEER Summary Stage 2000 manual
Notes
C540 Isthmus uteri C541 Endometrium C542 Myometrium C543 Fundus uteri C548 Overlapping lesion of corpus uteri C549 Corpus uteri C559 Uterus, NOS **Note 1:** This schema is based on the UICC chapter *Uterus-Uterine Sarcomas* pages 217-221. * Primary sites C541, C542, C548, and C549 are listed in the chapter heading but are not specified in the anatomic subsites in this chapter of the UICC manual; however, they are included in this schema and TNM staged if appropriate histology criteria are met. * Primary site group C53 is listed; however, is not included in this schema. See the *Cervix* schema. **Note 2:** The TNM 7th Edition staging reflects the new staging adopted by the International Federation of Gynecology and Obstetrics (FIGO) and utilizes three new staging schemas for cancer of the Corpus Uteri based on histology. The three new schemas are 1. Carcinoma and carcinosarcoma 2. Leiomyosarcoma and endometrial stromal sarcoma (ESS) 3. Adenosarcoma **Note 3:** The FIGO stages are based on surgical staging. (TNM stages are based on clinical and/or pathologic classification). **Note 4:** This schema is for leiomyosarcoma and endometrial stromal sarcoma (ESS). **Note 5:** When coding pay attention to the FIGO Editions and descriptions about cell and tumor types, disease extension, lymph node status and metastasis. **Note 6:** UICC 7th edition includes sarcomas of the cervix uteri with Uterine sarcomas and AJCC 7th edition limits it to sarcoma of the corpus uteri. SEER is not currently collecting TNM information on cervical sarcomas. **Note 7:** In addition to directly assigning TNM, Summary Stage 2000 (SS2000) must be captured. If directly assigning SS2000, use the *Corpus Uteri, Uterus, NOS* chapter on page 208 of the [SS2000 on-line manual](https://seer.cancer.gov/tools/ssm/ssm2000/SSSM2000-122012.pdf#page=208).Main Data Items
| Name | Default Value | Used in Derivation | NAACCR Item | Required By | Metadata | 
|---|---|---|---|---|---|
| Clinical T | Yes | NAACCR #940 tnmClinT | None | ||
| Clinical N | Yes | NAACCR #950 tnmClinN | None | ||
| Clinical M | Yes | NAACCR #960 tnmClinM | None | ||
| TNM Clin Stage Group | 99 | Yes | NAACCR #970 tnmClinStageGroup | None | |
| Pathologic T | Yes | NAACCR #880 tnmPathT | None | ||
| Pathologic N | Yes | NAACCR #890 tnmPathN | None | ||
| Pathologic M | Yes | NAACCR #900 tnmPathM | None | ||
| TNM Path Stage Group | 99 | Yes | NAACCR #910 tnmPathStageGroup | None | |
| SSF1: FIGO Stage | 988 | No | NAACCR #2880 csSiteSpecificFactor1 | CCCR/Canada COC | None | 
| SSF2: Peritoneal Cytology | 999 | No | NAACCR #2890 csSiteSpecificFactor2 | SEER | None | 
| SSF3: Number of Positive Pelvic Nodes | 999 | No | NAACCR #2900 csSiteSpecificFactor3 | CCCR/Canada COC SEER | None | 
| SSF4: Number of Examined Pelvic Nodes | 999 | No | NAACCR #2910 csSiteSpecificFactor4 | CCCR/Canada COC SEER | None | 
| SSF5: Number of Positive Para-Aortic Nodes | 999 | No | NAACCR #2920 csSiteSpecificFactor5 | CCCR/Canada COC SEER | None | 
| SSF6: Number of Examined Para-Aortic Nodes | 999 | No | NAACCR #2930 csSiteSpecificFactor6 | CCCR/Canada COC SEER | None | 
| SSF7: Percentage of Non-Endometrioid Cell Type in Mixed Histology Tumors | 988 | No | NAACCR #2861 csSiteSpecificFactor7 | None | None | 
| SSF8: Omentectomy | 988 | No | NAACCR #2862 csSiteSpecificFactor8 | None | None | 
Additional Data Items
| Name | Default Value | Used in Derivation | NAACCR Item | Required By | Metadata | 
|---|---|---|---|---|---|
| Year of Diagnosis | No | NAACCR #390 dateOfDiagnosis | None | ||
| Primary Site | Yes | NAACCR #400 primarySite | None | ||
| Histology | Yes | NAACCR #522 histologicTypeIcdO3 | None | ||
| RX Summ Systemic/Surgery Sequence | Yes | NAACCR #1639 rxSummSystemicSurSeq | None | ||
| RX Summ Surgery/Radiation Sequence | Yes | NAACCR #1380 rxSummSurgRadSeq | None | ||
| Regional Nodes Positive | Yes | NAACCR #820 regionalNodesPositive | None | 
Initial Context
Outputs
| Name | Default Value | Description | NAACCR Item | Metadata | 
|---|---|---|---|---|
| Derived Version | {{ctx_alg_version}} | None | None | |
| Derived SEER Clin Stage Group | 88 | NAACCR #3610 derivedSeerClinStgGrp | None | |
| Derived SEER Path Stage Group | 88 | NAACCR #3605 derivedSeerPathStgGrp | None | |
| Derived SEER Combined Stage Group | 88 | NAACCR #3614 derivedSeerCmbStgGrp | None | |
| Derived SEER Combined T | 88 | NAACCR #3616 derivedSeerCombinedT | None | |
| Derived SEER Combined N | 88 | NAACCR #3618 derivedSeerCombinedN | None | |
| Derived SEER Combined M | 88 | NAACCR #3620 derivedSeerCombinedM | None | |
| Derived SEER Combined T Source | <BLANK> | NAACCR #3622 derivedSeerCmbTSrc | None | |
| Derived SEER Combined N Source | <BLANK> | NAACCR #3624 derivedSeerCmbNSrc | None | |
| Derived SEER Combined M Source | <BLANK> | NAACCR #3626 derivedSeerCmbMSrc | None |